Skip to main content
NIH funding notice RFA-CA-25-010

Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) - Tobacco Use Treatment for Cancer Survivors (UG3/UH3 Clinical Trial Required)

Closed on December 6, 2024.

Posted
October 2, 2024
Close date
December 6, 2024
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.

Past awards
1
1 new
First-year cost
$1,594,797
Institutions
1
1 contact PI

Awards by fiscal year

Fiscal years 2014 to 2026.

Most frequent institutions

  1. WASHINGTON UNIVERSITY1

Most frequent study sections

  1. Special Emphasis Panel (ZCA1 RPRB-8 (M2))1
1 award under RFA-CA-25-010 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
FY2025Implementation science to scale and sustain tobacco treatment leveraging point of care paradigm and health information technology1UG3CA305777-01Brownson, Ross CChen, Li-ShiunRamsey, Alex TaylorWASHINGTON UNIVERSITY, MOFirst-year cost $1,594,797Study section ZCA1
Newest fiscal year first, then first-year cost.

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-12-0.1.3. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for departments

Open NIH notices that fit your faculty

See which open NIH funding notices fit each faculty member's CV, why each fits, and who won before.

RFA-CA-25-010: Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) - Tobacco Use Treatment for Cancer Survivors (UG3/UH3 Clinical Trial Required) | ScienceDex | ConductScience